Monitor cash runway: at current burn rate (~$1M/month), the $11.7M cash provides roughly 12 months of runway. The Phase 2 start in Q1 2027 is the next major catalyst.
GANX drugs
GANX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $1.08entry
- T+1 · 6d ago +2.78%α +1.46% · $1.11
- T+5 · due 10h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Gain Therapeutics reported Q3 2026 net loss of $0.07 per share, narrower than the $0.15 loss a year ago and better than the $-0.13 consensus. Cash burn continues with $11.7M on hand, and the company expects to start a Phase 2 trial of rexaceract in Q1 2027.
Key Financial Metrics
Key Facts
- Net loss per share $0.07 for Q3 2026 vs $0.15 in Q3 2025
- Cash and cash equivalents $11.7M as of Sep 30, 2026, down from $20.8M at Dec 31, 2025
- Phase 2 trial of rexaceract expected to begin in Q1 2027
- R&D expenses fell to $1.4M from $2.8M year-over-year
- Weighted average shares outstanding 43.8M for Q3 2026 vs 35.0M a year ago
Financial Impact
Net loss per share $0.07 vs consensus $-0.13; cash burn $9.1M in 9 months
Risk Factors
- Cash burn continues with no near-term revenue; may need to raise capital before Phase 2 completion
- Phase 2 trial design and enrollment delays could push timeline
- Pre-revenue clinical-stage biotech with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399309 |
Track record
15 reports on GANX
2 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +13.74% at T+60 after the May 26, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 17, 2026today Press Release Bullish 6/10 Entry $1.19 Now $1.18 −0.84% settles Nov 25
- Nov 10, 20267d ago Press Release Neutral 4/10 Viewing Entry $1.08 Now $1.18 +9.26% due Nov 17
- Oct 30, 202618d ago 3 Neutral 2/10 Entry $1.13 to $1.09 Now $1.18 +4.42% ▼ −3.54% −3.62% vs SPY
- Oct 28, 202620d ago 8-K Neutral 2/10 Entry $1.19 to $0.9604 Now $1.18 −0.84% ▼ −19.29% −14.57% vs SPY
- Oct 1, 20266w ago Press Release Neutral 4/10 Entry $1.72 to $1.62 Now $1.18 −31.40% ▼ −6.10% −7.41% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $1.72 to $1.62 Now $1.18 −31.40% ▼ −6.10% −7.41% vs SPY
- Aug 11, 202614w ago Press Release Bullish 6/10 Entry $2.06 to $2.03 Now $1.18 −42.72% ▼ −1.46% −1.05% vs SPY
- Jul 16, 202617w ago 8-K Neutral 4/10 Entry $1.66 to $1.82 Now $1.18 −28.92% ▲ +9.64% +11.31% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $2.03 to $1.81 Now $1.18 −41.87% ▼ −10.84% −11.44% vs SPY
- Jun 29, 202620w ago Press Release Bullish 5/10 Entry $2.03 to $1.81 Now $1.18 −41.87% ▼ −10.84% −11.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers